Freenome Holdings, Inc. IPO - What You Need to Know

Thinking about investing in Freenome? It is an exciting space, but biotech can be complex. Here is a breakdown of what you need to know, explained in plain English.

1. What does this company actually do?

Freenome is a biotech company building a platform to detect cancer early. Instead of invasive procedures like colonoscopies, Freenome tests blood samples. They look for "cell-free" markers—like DNA, RNA, and proteins—that cancer cells release into the blood. Their AI software combines these biological signals with medical data to spot cancer. They focus on creating simple, routine screening tests for colorectal cancer and other common cancers.

2. How are they going public?

Freenome is merging with Perceptive Capital Solutions Corp (PCSC), a Special Purpose Acquisition Company (SPAC). A SPAC is a publicly traded shell company with cash held in a trust. Once the deal closes, PCSC will move to Delaware, rename itself Freenome, Inc., and trade on the NASDAQ.

3. How much money are they raising?

Beyond the cash in the PCSC trust, Freenome secured a "PIPE" investment. Institutional investors agreed to buy 24 million shares at $10.00 each, bringing in $240 million. The deal requires a "minimum cash condition." After paying expenses and accounting for any investors who pull their money out, the company must keep at least $250 million in cash to move forward.

4. What will they do with the money?

Freenome is still in the research phase and has not yet made significant sales. They will use the new cash for:

• Clinical Trials: Funding the large, multi-year studies needed to get FDA approval for their tests.
• Infrastructure: Building larger labs to process blood samples at scale.
• R&D and Talent: Hiring experts in biology and AI to improve their testing software and expand their list of cancer screens.

5. Important Dates & How to Vote

If you own PCSC shares by the record date, you can vote at the extraordinary general meeting on July 9, 2026. Request your proxy materials by July 1, 2026.

A note on the vote: The PCSC board recommends voting "FOR" the merger. Keep in mind that PCSC’s directors own shares that could gain value if the deal succeeds, which may create a conflict of interest. The board reviewed about 200 potential companies before choosing Freenome.

6. Important: The "Governance" Fine Print

The new bylaws include rules that limit your influence as a shareholder:

• Bylaw Amendments: Changing company rules requires a "supermajority" vote of two-thirds of all shares.
• Director Removal: You can only remove board members "for cause," and it requires a two-thirds vote.
• No Written Consent: You cannot approve corporate actions via written consent. Everything must happen at a formal meeting.

7. What are the main risks?

• The "FDA Hurdle": Freenome’s business relies entirely on FDA approval. If they fail to meet safety or accuracy standards, they cannot sell their tests.
• Competition: The cancer screening market is crowded. Rivals like Exact Sciences and Guardant Health have more money and established products. Freenome must prove its AI is better than these existing options.
• Cash Burn: The company is currently losing money and expects to keep losing money for a while. If they run out of cash before they start selling products, they may need to sell more shares. This would reduce your ownership percentage and potentially lower the value of your investment.

Final Thoughts: Is this right for you?

Before you decide, ask yourself: Am I comfortable with a "long-game" investment? Freenome is a pre-revenue company, meaning they are betting everything on future technology and regulatory approval. If you are looking for immediate dividends or stable, established earnings, this may not be the right fit. If you are interested in the potential of AI-driven biotech and can handle the volatility of a startup, make sure you read the full SEC Prospectus (available on the SEC EDGAR website) to see the specific financial projections and legal risks before you commit your capital.

Disclaimer: I am an AI, not a financial advisor. Investing in biotech and SPAC mergers is high-risk. Never invest money you cannot afford to lose, and always read the company’s official "Prospectus" before buying shares.